Saxenda to Zepbound: what the GLP-1 switching data actually shows

What's this video probably claiming?

Based on the caption, @elizajane1983 is sharing a personal weight loss transformation that spans two different GLP-1 medications: liraglutide (Saxenda) starting July of one year, followed by a switch to tirzepatide (Zepbound) after hitting a plateau around February or March. The video likely frames GLP-1 receptor agonists broadly as life-changing, possibly implying that switching medications broke her plateau, and that tirzepatide delivered results where liraglutide eventually stopped working. With 184K views and hashtags mixing tirzepatide, semaglutide, and general fat loss content, the post almost certainly functions as implicit social proof for GLP-1 therapy, and may blur distinctions between these mechanistically different drugs. Personal transformation videos in this category routinely overstate how much the medication alone drove results, while underplaying diet, activity, and clinical monitoring. None of that makes her experience invalid, but it shapes how 184,000 viewers interpret what these drugs actually do.

What does the science actually show?

Liraglutide (Saxenda) at 3.0 mg daily produces average weight loss of roughly 8 percent of body weight over 56 weeks, per the SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM). Tirzepatide (Zepbound) is a dual GIP/GLP-1 agonist, a meaningfully different mechanism, and in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), participants on 15 mg weekly lost a mean of 20.9 percent of body weight over 72 weeks. That is not a modest upgrade. The plateau phenomenon this creator describes is real and documented: GLP-1 monotherapy weight loss typically plateaus between months 6 and 12 as physiological adaptations occur (Wilding et al., 2021, NEJM, STEP 1 data). Switching to a more potent or mechanistically broader agent can restart loss, though head-to-head switching trial data remains limited. The SURMOUNT-5 trial (2024) comparing tirzepatide to semaglutide directly showed tirzepatide produced roughly 47 percent greater weight loss, so the upgrade logic has some evidence behind it.

Where does the social media noise diverge from clinical reality?

The biggest distortion in GLP-1 transformation content is the implicit message that the drug does the work. Clinical trial participants receive structured dietary counseling, regular follow-up, and behavioral support alongside medication. SURMOUNT-1 included a 500 kcal/day deficit plus exercise guidance. Strip those out and real-world results are consistently lower than trial results. Second, casually mixing hashtags for tirzepatide and semaglutide implies they are interchangeable. They are not. Tirzepatide targets both GIP and GLP-1 receptors; semaglutide targets GLP-1 only. That difference is why SURMOUNT-5 data showed the gap it did. Third, "GLP-1 saved my life" framing, while emotionally understandable, normalizes these drugs for audiences who may not have metabolic disease and may not be appropriate candidates. Saxenda and Zepbound both carry FDA boxed warnings for thyroid C-cell tumors in rodent studies, and both require a clinical evaluation before prescribing. Transformation content routinely omits this entirely.

What should you actually know?

If you are plateauing on liraglutide or semaglutide, there is legitimate clinical rationale for discussing a switch to tirzepatide with your prescriber. The dual-agonist mechanism appears to drive meaningfully greater fat mass reduction, not just weight. A 2023 analysis by Coskun et al. in Cell Metabolism showed tirzepatide preferentially reduced fat mass while preserving lean mass better than GLP-1 monotherapy in preclinical models, and SURMOUNT-1 body composition data supported that direction. However, switching is a clinical decision that requires reviewing your current dose, titration history, side effect profile, and insurance coverage. Zepbound is not a compounded tirzepatide product, and compounded versions are not FDA-approved equivalents regardless of what social media suggests. Both liraglutide and tirzepatide require ongoing use to maintain weight loss: SURMOUNT-4 data showed participants regained roughly two-thirds of lost weight within a year of stopping tirzepatide. That is not a reason to avoid these drugs, but it is a reason to understand what you are committing to before your feed convinces you otherwise.